- Home
- SKM vs CDTX Comparison
SKM vs CDTX Comparison
Compare SKM & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKM | CDTX |
|---|---|---|
| Founded | 1984 | 2012 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7B | 7.0B |
| IPO Year | 1996 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SKM | CDTX |
|---|---|---|
| Price | $20.60 | $221.40 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $128.75 |
| AVG Volume (30 Days) | 670.1K | ★ 1.0M |
| Earning Date | 02-11-2026 | 11-06-2025 |
| Dividend Yield | ★ 4.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.89 | N/A |
| Revenue | ★ $12,327,044,068.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.05 | N/A |
| P/E Ratio | $19.37 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.66 | $15.22 |
| 52 Week High | $23.80 | $221.42 |
Technical Indicators
Market Signals| Indicator | SKM | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 57.38 | 84.92 |
| Support Level | $20.32 | $220.47 |
| Resistance Level | $20.75 | $221.42 |
| Average True Range (ATR) | 0.19 | 0.41 |
| MACD | 0.07 | -2.93 |
| Stochastic Oscillator | 83.49 | 97.68 |
Price Performance
Historical ComparisonAbout SKM SK Telecom Co. Ltd.
SK Telecom is South Korea's largest wireless telecom operator, with 32 million mobile customers. The firm also owns SK Broadband (formerly Hanaro Telecom), which has 7.2 million broadband customers and 9.5 million pay TV customers (6.7 million IPTV and 2.8 million Cable TV). While the firm also purchased stakes in businesses in security and semiconductor memory production as well as developing e-commerce and internet platform businesses, these were all spun off into the separate, SK Square business in November 2021. The company was formed after SK Group purchased KT's mobile business in 1994.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.